Conference Coverage

Revascularization in paraplegics best performed with PCI


 

AT THE 2018 CRT MEETING

– When paraplegics and quadriplegics have an acute MI and are candidates for revascularization, they should be treated preferentially with a percutaneous coronary intervention, according to data presented at the 2018 Cardiovascular Research Technologies meeting.

When compared 30 days after revascularization, the rates of major adverse cardiovascular events (MACE) following coronary artery bypass grafting (CABG) were 22% in the group with paraplegia or quadriplegia versus only 3.5% in those without loss of limb function. For percutaneous coronary intervention (PCI), the rates were 6% versus 2%, respectively, reported Xuming Dai, MD, PhD, an interventional cardiologist and assistant professor at the University of North Carolina at Chapel Hill.

Dr. Xuming Dai

Dr. Xuming Dai

A study of revascularization outcomes in patients with paraplegia or quadriplegia was undertaken after Dr. Dai was faced with two such patients, of whom one was ultimately referred for CABG. Concerned at the time about the suitability of CABG for patients with the potential for risk factors different from ambulatory patients, Dr. Dai consulted the literature.

“There are no guidelines, no studies. I could not even find a case report,” Dr. Dai recounted.

Pages

Recommended Reading

Targeting PCSK9 inhibitors to reap most benefit
MDedge Hematology and Oncology
Keep PCI patients on aspirin for noncardiac surgery
MDedge Hematology and Oncology
Prescribers mostly ignore clopidogrel pharmacogenomic profiling
MDedge Hematology and Oncology
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Hematology and Oncology
DEFUSE 3: Thrombectomy time window broadens
MDedge Hematology and Oncology
VIDEO: COMPASS shows stroke-clot aspiration noninferior to retrieval
MDedge Hematology and Oncology
AHA: Heart health helps optimize breast cancer outcomes
MDedge Hematology and Oncology
VIDEO: Rivaroxaban plus aspirin halves ischemic strokes
MDedge Hematology and Oncology
Thrombectomy’s success treating strokes prompts rethinking of selection criteria
MDedge Hematology and Oncology
200 cardiovascular drugs now in development
MDedge Hematology and Oncology